Measurement of natural (CD4+CD25high) and inducible (CD4+IL-10+) regulatory T cells in patients with systemic lupus erythematosus

Abnormalities of regulatory T cells may play an important role in the loss of self-tolerance, which is a major characteristic of lupus. The objective of this study was to determine the ratio and the number of natural CD4+CD25highFoxp3+ and inducible CD4+IL-10+ regulatory T cells in lupus patients and to search correlation with disease activity. Seventy-two Hungarian lupus patients were enrolled in the study. Fourty-one age- and sex matched healthy donors served as controls. Flow cytometry was used for the quantification of CD4+CD25high Foxp3+ (nTreg) and CD4+IL-10+ (iTreg) cells. The ratio (3.06 ± 1.45%) and the number (0.019 ± 0.012 × 109/L) of nTreg cells decreased in lupus significantly (P < 0.001 in both) as compared to normal controls (4.26 ± 1.01% and 0.039 ± 0.017 × 109/L). The ratio of iTreg cells were significantly higher in patients than in controls (20.92 ± 14.02% versus 15.49 ± 11.65%, P < 0.03), but the number of these cell type did not differ in significant manner (0.314 ± 0.236 × 109/L versus 0.259 ± 0.183 × 109/L). The 19 active patients were characterised by significantly higher disease activity index (SLEDAI 8.63 ± 2.95 versus 1.74 ± 1.68, P < 0.001) and anti-DNA concentration (117.85 ± 145.89 versus 37.36 ± 68.85 IU/mL, P = 0.001) as compered to the 52 inactive patients. Furthermore, active patients required higher dose of methylprednisolon than inactive ones (14.8 ± 10.6 versus 4.8 ± 3.4 mg/day, P < 0.001). However, we did not find statistical significant difference in the number and ratio of the examined cell populations regarding to disease activity. Altered ratio and number of both natural and inducible regulatory T cells may play a role in the pathogenesis of lupus. There are small but appreciable difference in the number of regulatory T cells between inactive patients and healthy controls. It suggests that immunoregulatory deficiencies are present in the inactive stage of the disease also. Lupus (2007) 16, 489—496.

[1]  F. Hodi.  Cytotoxic T-Lymphocyte–Associated Antigen-4 , 2007, Clinical Cancer Research.

[2]  P. Lipsky,et al.  TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. , 2006, Blood.

[3]  C. Gutiérrez,et al.  Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids , 2006, Annals of the rheumatic diseases.

[4]  Yao-Hsu Yang,et al.  Inverse correlation between CD4+ regulatory T‐cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus , 2006, Immunology.

[5]  P. Debré,et al.  Global Natural Regulatory T Cell Depletion in Active Systemic Lupus Erythematosus1 , 2005, The Journal of Immunology.

[6]  A. La Cava,et al.  Manipulation of immune regulation in systemic lupus erythematosus. , 2005, Autoimmunity reviews.

[7]  B. Hahn,et al.  Cellular and Molecular Mechanisms of Regulation of Autoantibody Production in Lupus , 2005, Annals of the New York Academy of Sciences.

[8]  E. Bettelli,et al.  Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Y. Sasaki,et al.  CD4(+)CD25high regulatory T cells in human pregnancy. , 2005, Journal of reproductive immunology.

[10]  J. Erikson,et al.  The regulation and activation of lupus‐associated B cells , 2005, Immunological reviews.

[11]  H. Markholst,et al.  In vivo control of diabetogenic T-cells by regulatory CD4+CD25+ T-cells expressing Foxp3. , 2005, Diabetes.

[12]  C. Akdis,et al.  Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. , 2004, The Journal of allergy and clinical immunology.

[13]  I. Sanz,et al.  B cells in human and murine systemic lupus erythematosus , 2004, Current opinion in rheumatology.

[14]  R. Wildin,et al.  Prospective immunological profiling in a case of immune dysregulation, polyendocrinopathy, enteropathy, X‐linked syndrome (IPEX) , 2004, Clinical and experimental immunology.

[15]  B. Stockinger,et al.  IL-10-Secreting Regulatory T Cells Do Not Express Foxp3 but Have Comparable Regulatory Function to Naturally Occurring CD4+CD25+ Regulatory T Cells 1 , 2004, The Journal of Immunology.

[16]  L-L Fung,et al.  Decreased CD4+CD25+ T Cells in Peripheral Blood of Patients with Systemic Lupus Erythematosus , 2004, Scandinavian journal of immunology.

[17]  J. Alcocer-Varela,et al.  Quantification of regulatory T cells in patients with systemic lupus erythematosus. , 2003, Journal of autoimmunity.

[18]  F. Ramsdell,et al.  Foxp3 and natural regulatory T cells: key to a cell lineage? , 2003, Immunity.

[19]  G. Szegedi,et al.  Plasmapheresis Modulates TH1/TH2 Imbalance in Patients with Systemic Lupus Erythematosus According to Measurement of Intracytoplasmic Cytokines , 2002, Autoimmunity.

[20]  R. Lechler,et al.  Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. , 2001, Blood.

[21]  D. Mason,et al.  Human CD4+CD25+ thymocytes and peripheral T cells have immune suppressive activity in vitro , 2001, European journal of immunology.

[22]  M. Nambiar,et al.  Immune cell signaling in lupus. , 2000, Current opinion in rheumatology.

[23]  Fiona Powrie,et al.  Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation , 2000, The Journal of experimental medicine.

[24]  Fiona Powrie,et al.  An Essential Role for Interleukin 10 in the Function of Regulatory T Cells That Inhibit Intestinal Inflammation , 1999, The Journal of experimental medicine.

[25]  V. Strand.  Biologic agents and innovative interventional approaches in the management of systemic lupus erythematosus. , 1999, Current opinion in rheumatology.

[26]  Ethan M. Shevach,et al.  CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production , 1998, The Journal of experimental medicine.

[27]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[28]  C. Goodnow.  Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[30]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[31]  K. Wood,et al.  The roles of CD25+CD4+ regulatory T cells in operational tolerance after living donor liver transplantation. , 2005, Transplantation proceedings.

[32]  坂口 志文.  Study on cellular events in postthymectomy autoimmune oophoritis in mice , 1983 .